Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)

被引:310
作者
Goodeve, Anne
Eikenboom, Jeroen
Castaman, Giancarlo
Rodeghiero, Francesco
Federici, Augusto B.
Batlle, Javier
Meyer, Dominique
Mazurier, Claudine
Goudemand, Jenny
Schneppenheim, Reinhard
Budde, Ulrich
Ingerslev, Jorgen
Habart, David
Vorlova, Zdena
Holmberg, Lars
Lethagen, Stefan
Pasi, John
Hill, Frank
Soteh, Mohammad Hashemi
Baronciani, Luciano
Hallden, Christer
Guilliatt, Andrea
Lester, Will
Peake, Ian
机构
[1] Univ Sheffield, Acad Unit Haematol, Sheffield, S Yorkshire, England
[2] Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands
[3] San Bortolo Hosp, Dept Hematol, Vicenza, Italy
[4] Univ Milan, Milan, Italy
[5] Hosp Teresa Herrera, Serv Hematol & Hematol, La Coruna, Spain
[6] INSERM, U143, Paris, France
[7] Lab Francais Fractionnement & Biotechnol, Lille, France
[8] Univ Lille, Lille, France
[9] Univ Hamburg, Med Ctr, Dept Pediat Hematol & Oncol, Hamburg, Germany
[10] Coagulat Lab, Hamburg, Germany
[11] Univ Aarhus, Ctr Haemophilia & Thrombosis, Hosp Skejby, Aarhus, Denmark
[12] Inst Hematol & Blood Transfus, Prague, Czech Republic
[13] Lund Univ, Dept Paediat, Lund, Sweden
[14] Lund Univ, Dept Coagulat Disorders, Malmo, Sweden
[15] Leicester Royal Infirm, Dept Pathol, Leicester LE2 7LX, Leics, England
[16] Childrens Hosp, Dept Haematol, Birmingham B16 8ET, W Midlands, England
关键词
D O I
10.1182/blood-2006-05-020784
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 1 von Willebrand disease (VWD) is characterized by a personal and family history of bleeding coincident with reduced levels of normal plasma von Willebrand factor (VWF). The molecular basis of the disorder is poorly understood. The aims of this study were to determine phenotype and genotype and their relationship in patients historically diagnosed with type 1 VWD. Families were recruited in 9 European countries based on previous type 1 VWD diagnosis. Bleeding symptoms were recorded, plasma phenotype analyzed, and VWF mutation analysis performed in all index cases (ICs). Phenotypic and molecular analysis stratified patients into those with or without phenotypes suggestive of qualitative VWF defects (abnormal multimers) and with or without mutations. A total of 105 of 150 ICs (70%) had mutations identified. A subgroup with abnormal multimers (38% of ICs, 57 of 150) showed a high prevalence of VWF gene mutations (95% of ICs, 54 of 57), whereas in those with qualitatively normal VWF, fewer mutations were identified (55% of ICs, 51 of 93). About one third of the type I VWD cases recruited could be reconsidered as type 2. The remaining group could be considered "true" type 1 VWD, although mutations were found in only 55%.
引用
收藏
页码:112 / 121
页数:10
相关论文
共 48 条
[1]   Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients [J].
Baronciani, L ;
Cozzi, G ;
Canciani, MT ;
Peyvandi, F ;
Srivastava, A ;
Federici, AB ;
Mannucci, PM .
BLOOD CELLS MOLECULES AND DISEASES, 2003, 30 (03) :264-270
[2]  
Baronciani L, 2000, THROMB HAEMOSTASIS, V84, P536
[3]   The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype [J].
Bowen, DJ ;
Collins, PW ;
Lester, W ;
Cumming, AM ;
Keeney, S ;
Grundy, P ;
Enayat, SM ;
Bolton-Maggs, PHB ;
Keeling, DM ;
Khair, K ;
Tait, RC ;
Wilde, JT ;
Pasi, JK ;
Hill, FGH .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (06) :830-836
[4]   An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13 [J].
Bowen, DJ ;
Collins, PW .
BLOOD, 2004, 103 (03) :941-947
[5]   Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents [J].
Caron, C ;
Mazurier, C ;
Goudemand, J .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (03) :716-718
[6]  
Casaña P, 1998, AM J HEMATOL, V59, P57, DOI 10.1002/(SICI)1096-8652(199809)59:1<57::AID-AJH11>3.0.CO
[7]  
2-Z
[8]  
Casaña P, 2001, HAEMATOLOGICA, V86, P414
[9]  
Castaman G, 1999, THROMB HAEMOSTASIS, V82, P1065
[10]  
Castaman G, 2000, THROMB HAEMOSTASIS, V84, P350